Drug-Induced Long QT Syndrome in Women
Abstract Congenital long QT syndromes (LQTS) are inherited heart diseases that can present as palpitations, syncope (fainting), seizures, cardiac arrest, and sudden death. Acquired LQTS mostly occurs as a result of exposure to an environmental stressor that is responsible for the excessive prolongation of the QT interval. The most common environmental stressor is adverse drug reactions, which can lead to drug-induced LQTS (di-LQTS). Female gender has been increasingly recognized as an independent risk factor for di-LQTS, which in females is influenced by other factors, including age, menstrual cycle, and hormone replacement therapy. The estrogen-mediated reduced repolarization reserve in women is believed to be responsible for their higher susceptibility to di-LQTS. More studies, especially randomized trials, should be carried out to confirm these findings, and elucidate the clinical impact of gender disparity in modifying the risk of di-LQTS in women, with the ultimate goal of promoting the clinical safety of medication. In this article, we review current knowledge about di-LQTS, specifically in women, and discuss methods for the prevention of di-LQTS in females..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
---|---|
Enthalten in: |
Advances in therapy - 30(2013), 9 vom: Sept., Seite 793-802 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Guoliang [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Cardiology |
---|
Anmerkungen: |
© Springer Healthcare 2013 |
---|
doi: |
10.1007/s12325-013-0056-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR024926442 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR024926442 | ||
003 | DE-627 | ||
005 | 20230519153655.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-013-0056-x |2 doi | |
035 | |a (DE-627)SPR024926442 | ||
035 | |a (SPR)s12325-013-0056-x-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Guoliang |e verfasserin |4 aut | |
245 | 1 | 0 | |a Drug-Induced Long QT Syndrome in Women |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer Healthcare 2013 | ||
520 | |a Abstract Congenital long QT syndromes (LQTS) are inherited heart diseases that can present as palpitations, syncope (fainting), seizures, cardiac arrest, and sudden death. Acquired LQTS mostly occurs as a result of exposure to an environmental stressor that is responsible for the excessive prolongation of the QT interval. The most common environmental stressor is adverse drug reactions, which can lead to drug-induced LQTS (di-LQTS). Female gender has been increasingly recognized as an independent risk factor for di-LQTS, which in females is influenced by other factors, including age, menstrual cycle, and hormone replacement therapy. The estrogen-mediated reduced repolarization reserve in women is believed to be responsible for their higher susceptibility to di-LQTS. More studies, especially randomized trials, should be carried out to confirm these findings, and elucidate the clinical impact of gender disparity in modifying the risk of di-LQTS in women, with the ultimate goal of promoting the clinical safety of medication. In this article, we review current knowledge about di-LQTS, specifically in women, and discuss methods for the prevention of di-LQTS in females. | ||
650 | 4 | |a Cardiology |7 (dpeaa)DE-He213 | |
650 | 4 | |a Drug adverse effects |7 (dpeaa)DE-He213 | |
650 | 4 | |a Female |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hormones |7 (dpeaa)DE-He213 | |
650 | 4 | |a Long QT syndrome |7 (dpeaa)DE-He213 | |
650 | 4 | |a Torsades de pointes |7 (dpeaa)DE-He213 | |
700 | 1 | |a Cheng, Gong |4 aut | |
700 | 1 | |a Wu, Jine |4 aut | |
700 | 1 | |a Zhou, Xin |4 aut | |
700 | 1 | |a Liu, Ping |4 aut | |
700 | 1 | |a Sun, Chaofeng |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 30(2013), 9 vom: Sept., Seite 793-802 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:30 |g year:2013 |g number:9 |g month:09 |g pages:793-802 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-013-0056-x |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 30 |j 2013 |e 9 |c 09 |h 793-802 |